Current practice and new developments in ovarian cancer chemotherapy

Abstract

Key content A combination of carboplatin and paclitaxel is the most commonly used treatment for advanced ovarian cancer, a chemosensitive disease with a high recurrence rate. Molecular targeted agents are being investigated as a novel strategy to improve the outcome of systemic therapy. Learning objectives To study the optimum timing of chemotherapy in relation to surgery and the role of intraperitoneal therapy. To be aware of current chemotherapy regimens used in the management of newly diagnosed and relapsed ovarian cancer and the rationale for using them. To understand current areas of research using novel agents in systemic therapy and different treatment strategies. Ethical issues It is important to consider the balance between benefit and side effects of treatment for women with relapsed disease. Patient choice is an important consideration for the selection of chemotherapy for relapsed ovarian cancer. Current treatment produces only a modest gain in outcome, therefore, every effort should be made to recruit women to clinical trials. Please cite this article as: Ali SN, Ledermann JA. Current practice and new developments in ovarian cancer chemotherapy. The Obstetrician & Gynaecologist 2007;9:265–269.

Primary testicular mucinous cystadenoma: Case report and literature review

“…Several groups described adjuvant chemotherapy with paclitaxel and carboplatin for ovarian tumours, and liposomal dauxorubicin or gemcitabine for relapsed disease. 11,12 However, its utility in primary testicular mucinous adenomas remains to be substantiated.…”